Reply to Bouva et al. Comment on "Dijkstra et al. A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone. Int. J. Neonatal Screen. 2023, 9, 66"

Affiliations

¹ Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
² Laboratory of Metabolic Diseases, Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
³ Section of Pediatric Gastroenterology and Hepatology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
⁴ Department of Genetics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
⁵ Princess Máxima Center for Pediatric Oncology, 3584 CX Utrecht, The Netherlands.
⁶ Department of Pediatric Infectious Disease and Immunology, Amalia's Children Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
⁷ Section Metabolic Diseases, Department of Pediatrics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

Allysa M Dijkstra et al. Int J Neonatal Screen. 2024.

. 2024 Sep 24;10(4):66.

doi: 10.3390/ijns10040066.

¹ Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
² Laboratory of Metabolic Diseases, Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
³ Section of Pediatric Gastroenterology and Hepatology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
⁴ Department of Genetics, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
⁵ Princess Máxima Center for Pediatric Oncology, 3584 CX Utrecht, The Netherlands.
⁶ Department of Pediatric Infectious Disease and Immunology, Amalia's Children Hospital, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
⁷ Section Metabolic Diseases, Department of Pediatrics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.

Abstract

We thank the authors for their comments [...].

The authors declare no conflicts of interest.

1. Bouva M.J., Maase R.E., van Elburg R.M. Comment on Dijkstra et al. A False-Negative Newborn Screen for Tyrosinemia Type 1—Need for Re-Evaluation of Newborn Screening with Succinylacetone. Int. J. Neonatal Screen. 2023, 9, 66. Int. J. Neonatal Screen. 2024;10:65. doi: 10.3390/ijns10040065. - DOI - PubMed
1. Dijkstra A.M., Evers-van Vliet K., Heiner-Fokkema M.R., Bodewes F.A.J.A., Bos D.K., Zsiros J., van Aerde K.J., Koop K., van Spronsen F.J., Lubout C.M.A. A False-Negative Newborn Screen for Tyrosinemia Type 1—Need for Re-Evaluation of Newborn Screening with Succinylacetone. Int. J. Neonatal Screen. 2023;9:66. doi: 10.3390/ijns9040066. - DOI - PMC - PubMed
1. van Vliet K., Dijkstra A.M., Bouva M.J., van der Krogt J., Bijsterveld K., van der Sluijs F., de Sain-van der Velden M.G., Koop K., Rossi A., Thomas J.A., et al. Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1. J. Inherit. Metab. Dis. 2023;46:1104–1113. doi: 10.1002/jimd.12669. - DOI - PubMed